Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a botulinum toxin presented as a sterile injectable for intramuscular use. By blocking acetylcholine release at the neuromuscular junction, it produces temporary, localized muscle paralysis that helps manage conditions characterized by excessive muscle activity. The effect can last months.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and cold‑chain logistics for this specialized biologic. The company adheres to stringent quality standards.

Letybo, a botulinum toxin type A preparation, is used in several neuromuscular and glandular disorders where temporary muscle relaxation or secretion reduction is desired.

- Cervical dystonia: reduces abnormal neck muscle contractions, improving head posture and pain. - Chronic migraine: decreases frequency of migraine attacks when administered prophylactically. - Upper limb spasticity: eases muscle stiffness in post‑stroke or cerebral palsy patients. - Blepharospasm: relaxes involuntary eyelid muscles, reducing spasms. - Severe axillary hyperhidrosis: diminishes excessive sweating by inhibiting sweat gland activity.

Adverse reactions to Letybo are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects: - Injection site pain - Bruising or hematoma - Headache - Flu‑like symptoms - Localized muscle weakness

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing - Respiratory compromise - Generalized muscle weakness - Spread of toxin effect to distant muscles - Anaphylactic reaction

Before using Letybo, clinicians should evaluate patient history and consider specific safety measures.

- Pregnancy: avoid unless benefits outweigh risks; safety data are limited. - Breastfeeding: use with caution; limited information on excretion in milk. - Neuromuscular disorders: assess risk of increased weakness in conditions such as myasthenia gravis. - Concomitant aminoglycoside or quinolone antibiotics: monitor for enhanced neuromuscular blockade. - Allergic reactions: do not administer to patients with known hypersensitivity to botulinum toxin or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo may interact with other medicines that affect neuromuscular transmission or toxin metabolism.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade, increasing risk of severe weakness. - Quinolone antibiotics: can enhance toxin effect on muscles, leading to respiratory complications. - General anesthetics (e.g., succinylcholine): may augment spread of toxin, causing prolonged paralysis.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce therapeutic efficacy of the toxin. - Beta‑adrenergic blockers: could alter muscle response, requiring dose adjustment.